Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Ipca Labs hosted its Q4 FY26 earnings conference call, where management reported an 8% increase in consolidated revenue to Rs.9,646 crore for FY26. The company also provided a positive outlook, guiding for a 12-13% consolidated growth for the current financial year.
Jun 04 2026 13:44:46
Ipca Labs Q4 aided by strong India business, export growth; ₹6 dividend declared
IPCA Laboratories reported a 14% year-on-year increase in net profit to ₹68 crore and a 10.5% rise in revenue to ₹2,247 crore for the fourth quarter of fiscal year 2025. The company also declared a dividend of ₹6 per share for the financial year.
May 29 2026 14:17:20
Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Change in Management
Ipca Laboratories' Board approved the re-appointment of Mr. Prashant Godha as Executive Director for a further five-year term, effective August 16, 2026. This re-appointment is subject to shareholder approval.
May 29 2026 13:59:48
Ipca Laboratories Ltd - 524494 - Board Meeting Outcome for Outcome Of Board Meeting
Ipca Laboratories board approved Q4 & FY26 financial results, with Q4 cons. net profit rising 341% YoY to ₹299.07 cr. The company also recommended a ₹6 dividend per share for FY26, setting August 7, 2026, as the record date.
May 29 2026 13:49:00
Read More